SV2001000338A - THE 5-ALKYLPIRIDE [2,3-D] PYRIMIDINES ARE INHIBITORS OF THYROSINE KINASES AND THAT DEPEND ON THE CYCLONE - Google Patents

THE 5-ALKYLPIRIDE [2,3-D] PYRIMIDINES ARE INHIBITORS OF THYROSINE KINASES AND THAT DEPEND ON THE CYCLONE

Info

Publication number
SV2001000338A
SV2001000338A SV2001000338A SV2001000338A SV2001000338A SV 2001000338 A SV2001000338 A SV 2001000338A SV 2001000338 A SV2001000338 A SV 2001000338A SV 2001000338 A SV2001000338 A SV 2001000338A SV 2001000338 A SV2001000338 A SV 2001000338A
Authority
SV
El Salvador
Prior art keywords
depend
pyrimidines
inhibitors
alkylpiride
cyclone
Prior art date
Application number
SV2001000338A
Other languages
Spanish (es)
Inventor
Richard John Booth
Ellen Myra Dobrusin
Peter Laurence Toogood
Scott Norman Vanderwel
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of SV2001000338A publication Critical patent/SV2001000338A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

ESTA INVENCIÓN SE REFIERE A 5-ALQUILPIRIDOPIRIMIDINAS COMO INHIBIDORES DE LAS CINASAS QUE DEPENDEN DE LA CICLINA, EN PARTICULAR DE LA CINASAS 4 QUE DEPENDEN DE LA CICLINA. LOS COMPUESTOS DE LA INVENCION SON UTILES PARA EL TRATAMIENTO DE LA INFLAMACION, LAS ENFERMEDADES PROLIFERATIVAS DE LAS CELULAS COMO EL CANCER Y LA RESTENOSIS, Y LAS ENFERMEDADES NEURODEGENERATIVAS, COMO LA ENFERMEDAD DE ALZHEIMER.THIS INVENTION REFERS TO 5-ALKYL PIRID-PYRIMIDINES AS INHIBITORS OF KINASAS THAT DEPEND ON CYCLINE, IN PARTICULAR OF KINASAS 4 THAT DEPEND ON CYCLINE. THE COMPOUNDS OF THE INVENTION ARE USEFUL FOR THE TREATMENT OF INFLAMMATION, PROLIFERATIVE CELL DISEASES LIKE CANCER AND RESTENOSIS, AND NEURODEGENERATIVE DISEASES, LIKE ALZHEIMER'S DISEASE.

SV2001000338A 2000-03-06 2001-03-05 THE 5-ALKYLPIRIDE [2,3-D] PYRIMIDINES ARE INHIBITORS OF THYROSINE KINASES AND THAT DEPEND ON THE CYCLONE SV2001000338A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US18712400P 2000-03-06 2000-03-06

Publications (1)

Publication Number Publication Date
SV2001000338A true SV2001000338A (en) 2001-11-30

Family

ID=22687699

Family Applications (1)

Application Number Title Priority Date Filing Date
SV2001000338A SV2001000338A (en) 2000-03-06 2001-03-05 THE 5-ALKYLPIRIDE [2,3-D] PYRIMIDINES ARE INHIBITORS OF THYROSINE KINASES AND THAT DEPEND ON THE CYCLONE

Country Status (36)

Country Link
EP (1) EP1268476A1 (en)
JP (1) JP2003528101A (en)
KR (1) KR20020075805A (en)
CN (1) CN1422268A (en)
AP (1) AP2002002643A0 (en)
AR (1) AR034119A1 (en)
AU (1) AU2001233028A1 (en)
BG (1) BG107161A (en)
BR (1) BR0109056A (en)
CA (1) CA2401368A1 (en)
CO (1) CO5280200A1 (en)
CR (1) CR6736A (en)
CZ (1) CZ20022929A3 (en)
DZ (1) DZ3308A1 (en)
EA (1) EA200200802A1 (en)
EE (1) EE200200506A (en)
GT (1) GT200100037A (en)
HN (1) HN2001000040A (en)
HR (1) HRP20020798A2 (en)
HU (1) HUP0300136A2 (en)
IL (1) IL151480A0 (en)
IS (1) IS6524A (en)
MA (1) MA26881A1 (en)
MX (1) MXPA02008535A (en)
NO (1) NO20024235L (en)
NZ (1) NZ520962A (en)
OA (1) OA12227A (en)
PA (1) PA8513201A1 (en)
PE (1) PE20011177A1 (en)
PL (1) PL358271A1 (en)
SK (1) SK12472002A3 (en)
SV (1) SV2001000338A (en)
TN (1) TNSN01036A1 (en)
WO (1) WO2001070741A1 (en)
YU (1) YU66502A (en)
ZA (1) ZA200207110B (en)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7053070B2 (en) * 2000-01-25 2006-05-30 Warner-Lambert Company Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors
US7235551B2 (en) 2000-03-02 2007-06-26 Smithkline Beecham Corporation 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
DK1333833T3 (en) 2000-10-23 2011-12-12 Glaxosmithkline Llc New trisubstituted 8H-pyridol [2,3-d] pyrimidin-7-one compound for the treatment of CSBP / RK / p38 kinase-mediated diseases
JP4064818B2 (en) * 2001-02-12 2008-03-19 エフ．ホフマン−ラ ロシュ アーゲー 6-substituted pyrido-pyrimidines
NZ527741A (en) 2001-02-26 2005-02-25 Tanabe Seiyaku Co Pyridopyrimidine or naphthyridine derivative
US20030100572A1 (en) * 2001-06-21 2003-05-29 Ariad Pharmaceuticals,Inc. Novel pyridopyrimidones and uses thereof
AU2002324450A1 (en) * 2001-06-21 2003-01-08 Ariad Pharmaceuticals, Inc. Novel pyridopyrimidines and uses thereof
WO2003062236A1 (en) 2002-01-22 2003-07-31 Warner-Lambert Company Llc 2-(PYRIDIN-2-YLAMINO)-PYRIDO[2,3d]PYRIMIDIN-7-ONES
CA2482022A1 (en) 2002-04-19 2003-10-30 Smithkline Beecham Corporation Novel compounds
DE60313339T2 (en) 2002-07-31 2008-01-03 Critical Outcome Technologies, Inc. PROTEIN TYROSINE KINASE INHIBITORS
ES2298563T3 (en) 2002-10-09 2008-05-16 Critical Outcome Technologies, Inc. INHIBITORS OF PROTEINS TIROSINA KINASAS.
BRPI0406809A (en) * 2003-01-17 2005-12-27 Warner Lambert Co 2-Aminopyridine substituted heterocycles as cell proliferation inhibitors
US6861422B2 (en) 2003-02-26 2005-03-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
WO2005020921A2 (en) 2003-08-29 2005-03-10 Exelixis, Inc. C-kit modulators and methods of use
NZ546634A (en) 2003-11-13 2010-01-29 Hoffmann La Roche Hydroxyalkyl substituted pyrido-7-pyrimidin-7-ones
DE102004029784A1 (en) 2004-06-21 2006-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Novel 2-Benzylaminodihydropteridinones, process for their preparation and their use as medicaments
DE102004033670A1 (en) 2004-07-09 2006-02-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg New pyridodihydropyrazinone, process for its preparation and its use as a medicament
FR2873118B1 (en) 2004-07-15 2007-11-23 Sanofi Synthelabo PYRIDO-PYRIMIDINE DERIVATIVES, THEIR APPLICATION IN THERAPEUTICS
US7728134B2 (en) 2004-08-14 2010-06-01 Boehringer Ingelheim International Gmbh Hydrates and polymorphs of 4[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament
US7759485B2 (en) 2004-08-14 2010-07-20 Boehringer Ingelheim International Gmbh Process for the manufacture of dihydropteridinones
US20060035903A1 (en) 2004-08-14 2006-02-16 Boehringer Ingelheim International Gmbh Storage stable perfusion solution for dihydropteridinones
US20060058311A1 (en) 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
US20060074088A1 (en) 2004-08-14 2006-04-06 Boehringer Ingelheim International Gmbh Dihydropteridinones for the treatment of cancer diseases
EP1630163A1 (en) 2004-08-25 2006-03-01 Boehringer Ingelheim Pharma GmbH & Co.KG Dihydropteridinones, methods for their preparation and their use as drugs
EP1786817A1 (en) * 2004-08-26 2007-05-23 Boehringer Ingelheim International GmbH Pteridinones used as plk (polo like kinases) inhibitors
DE102004058337A1 (en) 2004-12-02 2006-06-14 Boehringer Ingelheim Pharma Gmbh & Co. Kg Process for the preparation of fused piperazin-2-one derivatives
JP2008527007A (en) 2005-01-14 2008-07-24 ミレニアム・ファーマシューティカルズ・インコーポレイテッド Cinnamide and hydrocinnamide derivatives having Raf-kinase inhibitory activity
AR053450A1 (en) 2005-03-25 2007-05-09 Glaxo Group Ltd DERIVATIVES OF 3,4-DIHYDRO-PYRIMID (4,5-D) PYRIMIDIN-2- (1H) -ONA 1,5,7 TRISUSTITUTED AS INHIBITORS OF QUINASE P38
MY145281A (en) 2005-03-25 2012-01-13 Glaxo Group Ltd Novel compounds
WO2006110298A2 (en) 2005-03-25 2006-10-19 Glaxo Group Limited 8-alkyl/aryl-4-aryl-2-n- (alkylamino)-n'-substituted-n'-cyanoguanidino-8h-pyrido[2,3-d]pyrimidin-7-one compounds and use thereof
CA2603163A1 (en) 2005-03-25 2006-10-05 Glaxo Group Limited Process for preparing pyrido[2,3-d]pyrimidin-7-one and 3,4-dihydropyrimido[4,5-d]pyrimidin-2(1h)-one derivatives
US7737155B2 (en) * 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
FR2887882B1 (en) * 2005-07-01 2007-09-07 Sanofi Aventis Sa PYRIDO [2,3-D] PYRIMIDINE DERIVATIVES, THEIR PREPARATION, THEIR THERAPEUTIC APPLICATION
US7642270B2 (en) 2005-09-14 2010-01-05 Janssen Pharmaceutica N.V. 5-oxo-5,8-dihydro-pyrido-pyrimidine as inhibitors of c-fms kinase
TW200800983A (en) 2005-09-14 2008-01-01 Janssen Pharmaceutica Nv 5-oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of C-FMS kinase
EA016945B1 (en) * 2005-10-07 2012-08-30 Экселиксис, Инк. PYRIDOPYRIMIDINONE INHIBITORS OF PI3Kα
PT1940839E (en) * 2005-10-07 2013-10-10 Exelixis Inc Pyridopyrimidinone inhibitors of pi3kalpha
FR2896246B1 (en) 2006-01-13 2008-08-15 Sanofi Aventis Sa PYRIDO-PYRIMIDONE DERIVATIVES, THEIR PREPARATION, THEIR THERAPEUTIC APPLICATION
US7439358B2 (en) 2006-02-08 2008-10-21 Boehringer Ingelheim International Gmbh Specific salt, anhydrous and crystalline form of a dihydropteridione derivative
EA016388B1 (en) 2006-09-15 2012-04-30 Пфайзер Продактс Инк. Pyrido (2, 3-d) pyrimidin0ne compounds and their use as pi3 inhibitors
EP2084159A1 (en) * 2006-10-16 2009-08-05 GPC Biotech Inc. Pyrido ý2, 3-d¨pyrimidines and their use as kinase inhibitors
EP1914234A1 (en) * 2006-10-16 2008-04-23 GPC Biotech Inc. Pyrido[2,3-d]pyrimidines and their use as kinase inhibitors
WO2008055013A2 (en) * 2006-10-31 2008-05-08 Janssen Pharmaceutica N.V. 5-oxo-5,8 - dihydro - pyrido - pyrimidines as inhibitors of c-fms kinase
FR2910813B1 (en) 2006-12-28 2009-02-06 Sanofi Aventis Sa NEW THERAPEUTIC USE FOR THE TREATMENT OF LEUKEMIA
BRPI0809998B8 (en) * 2007-04-03 2021-05-25 Array Biopharma Inc imidazo[1,2-a]pyridine compound as receptor tyrosine kinase inhibitors, their uses, their preparation processes and pharmaceutical compositions
KR20100024932A (en) 2007-06-15 2010-03-08 반유 세이야꾸 가부시끼가이샤 Bicycloaniline derivative
JP5261487B2 (en) 2007-08-03 2013-08-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Crystal forms of dihydropteridinone derivatives
WO2009085185A1 (en) 2007-12-19 2009-07-09 Amgen Inc. Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors
CA2710039C (en) 2007-12-26 2018-07-03 Critical Outcome Technologies, Inc. Semicarbazones, thiosemicarbazones and related compounds and methods for treatment of cancer
EP2100894A1 (en) * 2008-03-12 2009-09-16 4Sc Ag Pyridopyrimidines used as Plk1 (polo-like kinase) inhibitors
WO2009126584A1 (en) 2008-04-07 2009-10-15 Amgen Inc. Gem-disubstituted and spirocyclic amino pyridines/pyrimidines as cell cycle inhibitors
EP2112150B1 (en) 2008-04-22 2013-10-16 Forma Therapeutics, Inc. Improved raf inhibitors
WO2010006438A1 (en) 2008-07-17 2010-01-21 Critical Outcome Technologies Inc. Thiosemicarbazone inhibitor compounds and cancer treatment methods
JP2012504628A (en) 2008-09-30 2012-02-23 エグゼリクシス， インコーポレイテッド Pyridopyrimidinone inhibitors of PI3Kα and mTOR
TW201100441A (en) 2009-06-01 2011-01-01 Osi Pharm Inc Amino pyrimidine anticancer compounds
KR20120104200A (en) * 2009-10-09 2012-09-20 아프락시스 인코포레이티드 8-ethyl-6-(aryl)pyrido[2,3-d]pyrimidin-7(8h)-ones for the treatment of cns disorders
WO2011075616A1 (en) 2009-12-18 2011-06-23 Temple University - Of The Commonwealth System Of Higher Education Substituted pyrido[2,3-d]pyrimidin-7(8h)-ones and therapeutic uses thereof
TW201139436A (en) 2010-02-09 2011-11-16 Exelixis Inc Methods of treating cancer using pyridopyrimidinone inhibitors of PI3K and mTOR in combination with autophagy inhibitors
US8987272B2 (en) 2010-04-01 2015-03-24 Critical Outcome Technologies Inc. Compounds and method for treatment of HIV
KR101434841B1 (en) * 2010-08-05 2014-08-29 템플 유니버시티-오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 2-substituted-8-alkyl-7-oxo-7,8-dihydropyrido[2,3-d] pyrimidine-6-carbonitriles and uses thereof
US8546566B2 (en) 2010-10-12 2013-10-01 Boehringer Ingelheim International Gmbh Process for manufacturing dihydropteridinones and intermediates thereof
US9358233B2 (en) 2010-11-29 2016-06-07 Boehringer Ingelheim International Gmbh Method for treating acute myeloid leukemia
JP6000273B2 (en) 2010-11-29 2016-09-28 オーエスアイ・ファーマシューティカルズ，エルエルシー Macrocyclic kinase inhibitor
EP2688887B1 (en) 2011-03-23 2015-05-13 Amgen Inc. Fused tricyclic dual inhibitors of cdk 4/6 and flt3
SI2710005T1 (en) * 2011-05-17 2017-03-31 Principia Biopharma Inc. Tyrosine kinase inhibitors
US9370535B2 (en) 2011-05-17 2016-06-21 Boehringer Ingelheim International Gmbh Method for treatment of advanced solid tumors
EP2817308B1 (en) * 2012-02-23 2016-09-07 AbbVie Inc. Pyridopyrimidinone inhibitors of kinases
SG11201505680RA (en) * 2013-02-21 2015-09-29 Pfizer Solid forms of a selective cdk4/6 inhibitor
JP2016525532A (en) 2013-07-26 2016-08-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Treatment of myelodysplastic syndrome
CN105294681B (en) 2014-07-26 2017-07-07 广东东阳光药业有限公司 Compound of CDK type small molecular inhibitors and application thereof
US9867831B2 (en) 2014-10-01 2018-01-16 Boehringer Ingelheim International Gmbh Combination treatment of acute myeloid leukemia and myelodysplastic syndrome
US10449195B2 (en) 2016-03-29 2019-10-22 Shenzhen Pharmacin Co., Ltd. Pharmaceutical formulation of palbociclib and a preparation method thereof
TWI646094B (en) * 2016-06-01 2019-01-01 大陸商貝達藥業股份有限公司 Crystal form of inhibitory protein kinase active compound and application thereof
CN109803968A (en) 2016-08-15 2019-05-24 辉瑞公司 Pyridopyrimidinone CDK2/4/6 inhibitor
JP7226804B2 (en) * 2017-03-03 2023-02-21 オークランド ユニサービシズ リミテッド FGFR kinase inhibitor and pharmaceutical use
KR20200131246A (en) 2018-02-15 2020-11-23 누베이션 바이오 인크. Heterocyclic compounds as kinase inhibitors
TW202035406A (en) * 2018-12-07 2020-10-01 大陸商杭州英創醫藥科技有限公司 Heterocyclic compound as CDK-HDAC dual pathway inhibitor
CN112759589B (en) * 2019-11-01 2022-04-08 暨南大学 Pyrimidopyridinones and their use
WO2021108803A1 (en) 2019-11-26 2021-06-03 Theravance Biopharma R&D Ip, Llc Fused pyrimidine pyridinone compounds as jak inhibitors
EP4310084A1 (en) * 2021-03-08 2024-01-24 Jinan University Pyridopyrimidine-based compound and application thereof
CN117720531A (en) * 2022-09-16 2024-03-19 华东师范大学 Pyridopyrimidine derivatives as RSK inhibitors and use thereof
WO2024099403A1 (en) * 2022-11-10 2024-05-16 北京普祺医药科技股份有限公司 Thioether compound having soft drug property and use thereof, and pharmaceutical composition and use thereof
WO2024107730A1 (en) * 2022-11-14 2024-05-23 Onconova Therapeutics, Inc. Methods and compositions for treating cancer

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5620981A (en) * 1995-05-03 1997-04-15 Warner-Lambert Company Pyrido [2,3-D]pyrimidines for inhibiting protein tyrosine kinase mediated cellular proliferation
JP2001509805A (en) * 1997-02-05 2001-07-24 ワーナー−ランバート・コンパニー Pyrido [2,3-D] pyrimidine and 4-aminopyrimidine as cell growth inhibitors
DE69939168D1 (en) * 1998-05-26 2008-09-04 Warner Lambert Co BICYCLIC PYRIMIDINES AND BICYCLIC 3,4-DIHYDROPYRIMIDINES AS INHIBITORS OF CELL REPRODUCTION

Also Published As

Publication number Publication date
DZ3308A1 (en) 2001-09-27
NZ520962A (en) 2003-09-26
AU2001233028A1 (en) 2001-10-03
KR20020075805A (en) 2002-10-05
CR6736A (en) 2004-03-10
WO2001070741A1 (en) 2001-09-27
NO20024235D0 (en) 2002-09-05
PA8513201A1 (en) 2003-06-30
JP2003528101A (en) 2003-09-24
GT200100037A (en) 2002-03-04
IL151480A0 (en) 2003-04-10
CA2401368A1 (en) 2001-09-27
OA12227A (en) 2004-03-18
EP1268476A1 (en) 2003-01-02
TNSN01036A1 (en) 2005-11-10
EA200200802A1 (en) 2003-02-27
IS6524A (en) 2002-08-23
MA26881A1 (en) 2004-12-20
CO5280200A1 (en) 2003-05-30
AP2002002643A0 (en) 2002-12-31
HN2001000040A (en) 2001-09-06
HRP20020798A2 (en) 2004-02-29
YU66502A (en) 2005-09-19
BG107161A (en) 2003-06-30
EE200200506A (en) 2004-02-16
SK12472002A3 (en) 2003-04-01
AR034119A1 (en) 2004-02-04
ZA200207110B (en) 2003-12-04
MXPA02008535A (en) 2002-12-13
PE20011177A1 (en) 2001-11-23
CZ20022929A3 (en) 2003-02-12
HUP0300136A2 (en) 2003-05-28
BR0109056A (en) 2003-06-03
NO20024235L (en) 2002-11-05
CN1422268A (en) 2003-06-04
PL358271A1 (en) 2004-08-09

Similar Documents

Publication Publication Date Title
SV2001000338A (en) THE 5-ALKYLPIRIDE [2,3-D] PYRIMIDINES ARE INHIBITORS OF THYROSINE KINASES AND THAT DEPEND ON THE CYCLONE
HN2003000039A (en) 2- (PIRIMIDIN-2-ILAMINO) -PIRIDO [2,3-d] PIRIMIDIN-7-ONAS
CO4340688A1 (en) QUINAZOLINE DERIVATIVES AND PROCEDURES FOR THE USE OF THE SAME, AS AGENTS AGAINST CANCER, IN MAMMALS.
DOP2004000949A (en) PIRROLO DERIVATIVES [3,4-C] PIRAZOL ASSETS AS KINASE INHIBITORS, PROCESS FOR PREPARATION AND PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THE SAME
CR8102A (en) DERIVATIVES OF PIRAZOLO-QUINAZOLINA, PROCEDURE FOR PREPARATION AND ITS USE AS QUINASE INHIBITORS
BRPI0207961A8 (en) USE OF EPOTHYLONE AND CAPECITABIN ANALOGS TO MANUFACTURE DRUG TO TREAT SOLID CANCEROUS TUMORS AND KIT COMPRISING THE SAID COMPOUNDS.
NO20060386L (en) Isetionate salt of a selective CDK4 inhibitor
CU20080223A7 (en) PIRROLO-PYRIMIDINE COMPOUNDS AND THEIR USES
UY27222A1 (en) PIRAZOLOPIRIMIDINAS AS THERAPEUTIC AGENTS
ECSP066643A (en) PIRIDO [2,3-d] PIRIMIDINA-2,4-DIAMINAS AS PDE 2 INHIBITORS
UY27714A1 (en) 2 - HETEROARIL - CDK INHIBITING PYRIMIDINES, ITS PREPARATION AND ITS USE AS MEDICATIONS.
UY29420A1 (en) DERIVATIVES OF 2-PIRIDONA, COMPOSITIONS THAT CONTAIN THEM, PREPARATION AND APPLICATION PROCESSES
UY27226A1 (en) PIRAZOLOPIRIMIDINAS AS THERAPEUTIC AGENTS
UY29796A1 (en) NEW COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL, PSYCHIATRIC OR PAIN DISORDERS
GT200500020A (en) DERIVATIVES OF 1H-TIENO [2,3-C] PIRAZOL USEFUL AS QUINASE INHIBITORS.
SV2002000602A (en) PHARMACEUTICAL COMPOUNDS REF.PCS10 398AJER / BB
GT200500113A (en) PIRIMIDINE DERIVATIVES TO TREAT ANOMALO CELLULAR GROWTH
CY1110666T1 (en) PYRAZOLOPYRIMIDINES SUITABLE FOR CANCER DISEASE TREATMENT
PT1325011E (en) METHODS AND COMPOUNDS FOR TREATMENT OF PROLIFERATIVE DISEASES
BR0209645A (en) Oxazole and furopyrimidines and their use as medicines
HN2003000080A (en) INDOLIL-UREA DERIVED FROM USEFUL TIENOPIRIDINS AS ANTIANGIOGEN AGENTS AND PROCEDURES FOR USE
UY28108A1 (en) NEW DERIVATIVES OF ARILEN- (2-AMINO-FENIL) -CARBOXAMIDA, ITS ELABORATION AND ITS USE AS PHARMACEUTICAL AGENTS
IS8059A (en) Treatment of proliferative diseases with epothilone derivatives and radiation
HN2000000078A (en) AMIDAS REPLACED FENILCICLOHEXANOCARBOXILICO ACID AND ITS USE AS INHIBITORS OF ADENOSINE INCORPORATION
UY27132A1 (en) NAFTOSTIRILS

Legal Events

Date Code Title Description
FD Lapse